SciSparc Ltd. (SPRC) Form 6-K — Sep 24, 2026

$SPRCForm 6-KFiled Sep 24, 2026, 6:26 AM ET0001213900-26-102810Original filing

SciSparc announced that its majority-owned subsidiary NeuroThera Labs highlighted the expansion of its U.S. patent portfolio through its collaboration with Clearmind Medicine. Three U.S. patent applications were published covering proprietary combinations of NeuroThera's PEA (palmitoylethanolamide) technology with LSD, ketamine and ibogaine, targeting indications including depression, PTSD, pain and substance use disorders.

Key figures

Indications: ["depression","PTSD","pain","substance use disorders"]
Compounds covered: ["LSD","ketamine","ibogaine"]
Us patent applications published: 3

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.